Sanofi places new $1.9B bet even as its last sours; Sam Waksal's new biotech ideas; Cell therapy time for Roche; and more
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.